The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Peak ALC after CAR-T infusion predicts clinical response in aggressive lymphoma
Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, talks on the association between peak absolute lymphocyte count (ALC) after CAR-T infusion and clinical response in aggressive lymphoma. A higher absolute lymphocyte ALC peak was associated with increased complete response rates and a longer duration of response in the first 6 months post-CAR-T cell infusion. Increasing ALC levels also correlated with CAR-T cell expansion and higher rates of progression-free survival (PFS) and overall-survival (OS). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
